Abstract: The invention provides stable pharmaceutical preparations for topical and nasal uses, comprising Mupirocin calcium amorphous as an anti-microbial active agent therein, dissolved in a pharmaceutically acceptable solvent providing stability therefore.

Abstract: Processes are provided for the preparation of orally administrable, yellow and powdery compositions essentially consisting of particles composed of a homogeneous mixture of an amorphous Cefditoren pivoxil substance with a water soluble high-molecular additive. These compositions can be produced by dissolving crystalline Cefditoren pivoxil substance and the water-soluble high-molecular additive in an aqueous solution of an acid, then neutralizing the resultant solution, to co-precipitate the product, and drying the thus precipitated product, followed by recovering the product in the form of the above-mentioned particles.

Abstract: The present invention relates to an antimicrobial wipe comprising a porous or absorbent sheet impregnated with an antimicrobial cleansing composition, wherein the antimicrobial cleansing composition comprises from about 0.001% to about 5.0%, by weight of the antimicrobial cleansing composition, of an antimicrobial active; from about 0.05% to about 10%, by weight of the antimicrobial cleansing composition, of an anionic surfactant; from about 0.1% to about 10%, by weight of the antimicrobial cleansing composition, of a proton donating agent; and from about 3% to about 99.85%, by weight of the antimicrobial cleansing composition, water; wherein the composition is adjusted to a pH of from about 3.0 to about 6.0; wherein the antimicrobial cleansing composition has a Gram Positive Residual Effectiveness Index of greater than about 0.5; and wherein the antimicrobial cleansing composition has a Mildness Index of less than about 0.3.

Abstract: Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4′-4″-fluorophenyl-2′-cyclopropyl-quinolin-3′-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.

Abstract: A composition is provided that has been specially adapted for parenteral administration, e.g., intranasal, intramuscular, subcutaneous, transdernal or intraveneous administration, wherein the composition is comprised of at least one anti-protozoal drug in a therapeutically effective amount for the treatment or prevention of protozoan infections in man and in animals. In one embodiment, the anti-protozoal drug is a triazine-based anticoccidial agent, e.g., a triazinedione or triazinetrione such as diclazuril, toltrazuril, sulfonotoltrazuril or water-soluble sodium salts thereof. In a presently preferred embodiment, the triazine-based anticoccidial agent is sulfonototrazuril. Methods of treatment of protozoal infections in man and animals are also provided.

Abstract: The present invention relates to N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitors enzyme activity, pharmaceutical compositions comprising such inhibitors, and methods of their use to inhibit NAALADase enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases, pain and diabetic neuropathy.

Abstract: An oral adhesive preparation has a substrate and a pressure-sensitive adhesive layer provided on at least one surface of the substrate, in which the pressure-sensitive adhesive layer contains a medicine, and is substantially insoluble in water or absorbs substantially no water. Further, an oral adhesive sheet comprising a separator release-treated on one or both surfaces thereof and a plurality of sections for application to oral mucous membrane mounted on at least one surface of the separator in a specified 2 to 5 by 2 to 5 arrangement with a specified proportion of a minimum inner diameter, Dp, of an incircle passing a center of gravity, W, of a section to a shortest distance, Di, of an adjacent section is 1.5 to 6. The substrate is preferably cloth such as non-woven fabric. Sections containing a local anesthetic can be used in surface anesthesia in dentistry.

Abstract: The present invention relates to a rinse-off antimicrobial cleansing composition comprising from about 0.1% to about 5.0%, by weight of the cleansing composition, of an antimicrobial active; from about 9% to about 14%, by weight of the cleansing composition, of an anionic surfactant, wherein at least about 67% of the anionic surfactant is selected from the group consisting of Class A surfactants, Class C surfactants, and mixtures thereof, wherein the ratio of Class A surfactant to Class C is from about 4:1 to about 1.5:1, and wherein the total anionic surfactant comprises less than about 50% of the ammonium counter cation salt; from about 4% to about 8%, by weight of the cleansing composition, of a proton donating agent having a Biological Activity Index, Z, of greater than about 0.

Abstract: A method for treating a patient having a wound is described. The method includes administering an amount of a chemodenervating agent such that healing of the wound is enhanced. The method is illustrated by detailing the mean differences of the scores of the paired experimental and control scars across three observers.

Abstract: The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.

Abstract: The pyrazoles and pyrazolopyrimidines of the formula wherein R1, R2, R3, R4 and A are as defined herein, have corticotropin releasing factor (CRF) antagonist activity. As such, they are effective in the treatment of a wide range of diseases including stress-related illnesses.

Abstract: Exogenous L-carnitine in the form of an equimolar amount of L-carnitine acid fumarate is administered to reduce increased volume and fluidity of stools and frequency of bowel movements relative to their usual pattern brought about by the administration of exogenous L-carnitine. Preferably nutritionally dietetically or therapeutically effective amount of L-carnitine acid fumarate is administered orally in the form of a tablet pill, capsule or powder.

Abstract: Methods and compositions that act as specific inhibitors of ALF activity for the prophylaxis and treatment of anthrax infections.

Abstract: The present invention relates to compositions and methods for calcifying dental tissue, e.g., preventing or treating dental hypersensitivity. An oral composition of arginine bicarbonate and calcium carbonate promotes the formation of dentinal tubule plugs aided by combining calcium and phosphate in the fluid. In a specific example, an arginine bicarbonate/calcium carbonate mixture blocked dentinal tubules in a model system. In addition to treating dentinal sensitivity, the compositions and methods of the invention provide for calcifying exposed tooth pulp, calcifying the base or all of a pit or fissure in a tooth, and treating a carious lesion.

Abstract: A tooth polishing agent for effectively removing stains such as tobacco tar and tartar with the use of a toothbrush and gentle brushing, using only a small amount of the tooth polishing agent. The improved tooth polishing agent of the present invention generates negative ions in the mouth, effectively cleaning the teeth without the use of large amounts of abrasives or aggressive brushing. The negative ions also act to improve circulation of the blood in the gums and prevent gum disease. The tooth polishing agent of the present invention is constituted with the powdered form of a multi-element mineral, which negatively ionizes water. This multi-element mineral contains a balance of elements, including silica-like perlite, pitchstone and tourmaline.

Abstract: Astaxanthin is a potent antioxidant, over 500 times more powerful than Vitamin E and 10 times stronger than other carotenoids such as zeaxanthin, lutein, canthaxanthin and beta-carotene. Astaxanthin has also been shown to enhance and modulate the immune system. Disclosed is a method and treatment for retarding and preventing sunburns. The method comprises administering a source of astaxanthin in a therapeutically effective amount to prevent and retard sunburns.

Abstract: Compositions comprising colchicine and at least one amino-salicylic acid derivative, preferably olsalazine is used for treatment of prophylaxis of constipation.

Abstract: The present invention relates to an oral composition containing a zinc compound containing free available zinc ion and at least one stabilized or stable Eh raising compound distributed in an oral vehicle. The present invention further relates to a method of inhibiting the formation of sulfur containing anions and preventing a reduction in the Eh of the oral cavity. A method of reducing oral malodor and gingivitis and periodontitis is also provided by this invention.

Abstract: The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into a sympathetic ganglion, thereby reducing an inhibitory effect upon insulin secretion.

Abstract: A bacteria killing oral bactericide is applied to a user's teeth. All surfaces of the teeth are covered with the oral bactericide. The oral bactericide is left disposed on the teeth during the sleeping hours during which the oral bactericide both destroys harmful bacteria, plaque-building bacteria, and protects the teeth from any damage which may be caused by harmful bacteria. The oral bactericide is removed by brushing the teeth.